
DIVISION OF NEUROPHARMACOLOGICAL DRUG PRODUCTS
PRELIMINARY CLINICAL SAFETY REVIEW OF NDA

Brand Name: Xyrem
Generic Name: Sodium Oxybate
Sponsor: Orphan Medical, Inc.
Indication: Narcolepsy
NDA Number: 21196
Original Receipt Date: 10/3/00
Clinical Reviewer: Ranjit B. Mani, M.D.
Review Author: Ranjit B. Mani, M.D.
Review Completed: 5/3/01

Table of Contents

1. REVIEW SOURCES	7
1.1 MATERIALS FROM NDA.....	7
1.2 RELATED REVIEWS, CONSULTS.....	7
1.3 OTHER REVIEWS	7
2. BACKGROUND.....	8
2.1 INDICATION	8
2.2 IMPORTANT INFORMATION FROM PHARMACOLOGICALLY RELATED AGENTS.....	8
2.3 ADMINISTRATIVE HISTORY	8
2.4 PROPOSED LABELING	8
2.5 FOREIGN MARKETING	8
2.6 MISCELLANEOUS BACKGROUND INFORMATION.....	9
3. CHEMISTRY, MANUFACTURING AND CONTROLS.....	9
4. TOXICOLOGY.....	10
5. CLINICAL DATA SOURCES.....	10
5.1 SOURCES OF ALL DATA IN INTEGRATED SUMMARY OF SAFETY.....	10
5.1.1 Study Type.....	10
5.1.2 Number Of Unique Narcoleptic Patients And Healthy Subjects In Integrated Summary Of Safety 11	
5.1.3 Demographics.....	12
5.1.4 Extent of Exposures.....	13
5.2 CUT-OFF DATE FOR DATA IN INTEGRATED SUMMARY OF SAFETY	14
5.3 PRIMARY DATA SOURCES	14
5.3.1 Efficacy And Long-Term Safety Studies.....	14
5.3.2 Pharmacokinetic Studies.....	15
5.4 SECONDARY DATA SOURCES	15
5.5 OTHER DATA SOURCES	15
5.6 ADEQUACY OF HUMAN EXPERIENCE.....	16
5.7 DATA QUALITY AND COMPLETENESS.....	16
6. HUMAN PHARMACOKINETICS	16
7. TABULAR SUMMARY OF KEY EFFICACY STUDIES.....	17
7.1 STUDY OMC-GHB-2	17
7.2 SCRIMA STUDY.....	17
7.3 LAMMERS STUDY	18
7.4 STUDY OMC-SXB-21.....	18
8. INTEGRATED REVIEW OF SAFETY	18
8.1 BACKGROUND AND METHODOLOGY	18
8.2 DEATHS.....	19
8.2.1 Tabular Summary Of Deaths	19
8.2.2 Conclusions Regarding Deaths.....	19
8.3 SERIOUS ADVERSE EVENTS.....	19
8.3.1 Serious Adverse Events In Integrated Clinical Trials.....	20
8.3.2 Serious Adverse Events In Scharf Study.....	23
8.4 DROPOUTS AND "OTHER SIGNIFICANT ADVERSE EVENTS"	25
8.4.1 Adverse Event Discontinuations In Integrated Clinical Trials	26
8.4.2 Adverse Event Discontinuations In Scharf Trial.....	31

- 8.4.3 *Adverse Event Discontinuations In Integrated Pharmacokinetic Trials* 35
- 8.5 ADVERSE EVENTS INCIDENCE TABLES 35
 - 8.5.1 *Approach to Eliciting Adverse Events*..... 35
 - 8.5.2 *Adverse Events Categorization and Preferred Terms*..... 36
 - 8.5.3 *Key Adverse Events Tables* 36
 - 8.5.4 *Common and Drug-Related Side Effects*..... 41
 - 8.5.5 *Additional Analyses and Explorations* 42
- 8.6 LABORATORY FINDINGS 56
 - 8.6.1 *Extent of Laboratory Testing During Development* 56
 - 8.6.2 *Selection of Studies for Overall Drug-Control Comparisons And Other Analyses*..... 57
 - 8.6.3 *Standard Analyses and Explorations of Laboratory Data* 57
- 8.7 VITAL SIGNS 64
 - 8.7.1 *Extent of Vital Sign Testing During Development* 64
 - 8.7.2 *Selection of Studies for Overall Drug-Control Comparisons And Other Analyses*..... 65
 - 8.7.3 *Standard Analyses and Explorations of Vital Sign Data* 65
- 8.8 ECG 67
 - 8.8.1 *Extent of Electrocardiogram Testing During Development*..... 67
 - 8.8.2 *Selection of Studies for Overall Drug-Control Comparisons And Other Analyses*..... 67
 - 8.8.3 *Standard Analyses and Explorations of Electrocardiogram Data*..... 67
- 8.9 WITHDRAWAL PHENOMENON AND ABUSE POTENTIAL 70
 - 8.9.1 *Background*..... 70
 - 8.9.2 *Purposes For Which GHB Is Misused Or Abused* 70
 - 8.9.3 *Clinical Psychological And Physical Dependence In Humans*..... 70
 - 8.9.4 *Rebound Symptoms With GHB Withdrawal*..... 71
 - 8.9.5 *Extent Of GHB Abuse In The United States*..... 72
 - 8.9.6 *Pre-Clinical Studies Of Drug Abuse Potential* 72
- 8.10 HUMAN REPRODUCTION DATA..... 72
- 8.11 OVERDOSE..... 73
 - 8.11.1 *Background*..... 73
 - 8.11.2 *Clinical Presentation* 73
 - 8.11.3 *Treatment*..... 74
- 9. STUDY OMC-SXB-20 74**
 - 9.1 OBJECTIVES..... 74
 - 9.1.1 *Primary*..... 74
 - 9.1.2 *Secondary*..... 74
 - 9.2 DESIGN/SUMMARY OF INVESTIGATIONAL PLAN..... 75
 - 9.2.1 *Phase I*..... 75
 - 9.2.2 *Phase II*..... 75
 - 9.3 DURATION 75
 - 9.4 SAMPLE SIZE 75
 - 9.5 KEY INCLUSION CRITERIA..... 75
 - 9.6 KEY EXCLUSION CRITERIA..... 76
 - 9.7 DOSAGE 76
 - 9.8 OUTCOME MEASURES 76
 - 9.8.1 *Primary Efficacy Measures*..... 76
 - 9.8.2 *Secondary Efficacy Measures* 77
 - 9.8.3 *Safety Measures* 77
 - 9.9 ANALYSIS PLAN 77
 - 9.10 RESULTS 78
 - 9.10.1 *Patient Disposition*..... 78
 - 9.10.2 *Baseline And Demographic Characteristics* 78
 - 9.10.3 *Tricyclic Antidepressants, Selective Serotonin Re-Uptake Inhibitors And Hypnotics At Baseline* 78
 - 9.10.4 *Protocol Deviations* 78
 - 9.10.5 *Treatment Compliance*..... 79

9.10.6 Extent Of Exposure 79

9.10.7 Efficacy Results 79

9.10.8 Safety Results 79

9.11 REVIEWER’S COMMENTS 81

10. SAFETY DATA FROM STUDY OMC-SXB-21 81

10.1 BRIEF SUMMARY OF STUDY PROTOCOL 81

10.1.1 Objective 81

10.1.2 Design 81

10.1.3 Duration 82

10.1.4 Sample Size 82

10.1.5 Key Inclusion Criteria 82

10.1.6 Key Exclusion Criteria 83

10.1.7 Concomitant Medications 83

10.1.8 Dosage 83

10.1.9 Schedule 83

10.1.10 Outcome Measures 84

10.1.11 Analysis Plan 84

10.2 PROTOCOL AMENDMENTS 85

10.3 ACTUAL ANALYSES PERFORMED 85

10.4 EFFICACY RESULTS 85

10.4.1 Patient Disposition 85

10.4.2 Protocol Deviations 86

10.4.3 Medication Compliance 86

10.4.4 Baseline And Other Demographic Characteristics 87

10.4.5 Primary Efficacy Analysis 87

10.4.6 Analysis Of Secondary Efficacy Measures 89

10.5 SAFETY RESULTS 89

10.5.1 Exposure 89

10.5.2 Deaths, Serious Adverse Events And Adverse Event Discontinuations 90

10.5.3 Other Adverse Events 90

10.5.4 Laboratory Data 92

10.5.5 Vital Signs 93

10.6 SPONSOR’S CONCLUSIONS REGARDING SAFETY 93

10.7 REVIEWER’S COMMENTS 93

11. KEY INFORMATION FROM INTEGRATED SUMMARY OF SAFETY AND OMC-SXB-21 SAFETY DATA 94

11.1 ALL ADVERSE EVENTS 94

11.2 DEATHS 94

11.3 SERIOUS ADVERSE EVENTS 94

11.4 ADVERSE EVENT DISCONTINUATIONS 95

11.5 LABORATORY DATA 95

11.6 ELECTROCARDIOGRAMS 96

11.7 VITAL SIGNS 96

11.8 WITHDRAWAL PHENOMENA 96

12. LITERATURE REVIEW 96

12.1 PUBLISHED STUDIES CONDUCTED IN HEALTHY INDIVIDUALS 96

12.2 PUBLISHED STUDIES CONDUCTED FOR SPECIFIC MEDICAL INDICATIONS 97

13. 120-DAY SAFETY UPDATE 98

13.1 CONTENTS 98

13.2 OUTLINE OF PROTOCOL FOR OMC-SXB-7 99

13.2.1 Objectives 99

13.2.2 Design 99

13.2.3	<i>Inclusion Criteria</i>	99
13.2.4	<i>Exclusion Criteria</i>	100
13.2.5	<i>Sample Size</i>	100
13.2.6	<i>Duration</i>	100
13.2.7	<i>Dosage</i>	100
13.2.8	<i>Concomitant Medication</i>	100
13.2.9	<i>Schedule</i>	101
13.2.10	<i>Statistical Considerations</i>	101
13.2.11	<i>Safety Monitoring</i>	101
13.3	PROTOCOL AMENDMENTS.....	101
13.4	PATIENT DISPOSITION.....	101
13.5	DEMOGRAPHICS.....	101
13.6	DOSAGE.....	102
13.7	PATIENT EXPOSURE.....	102
13.8	SAFETY RESULTS.....	103
13.8.1	<i>All Adverse Events</i>	103
13.8.2	<i>Adverse Event Tables</i>	103
13.9	DEATHS.....	104
13.10	SERIOUS ADVERSE EVENTS.....	105
13.10.1	<i>Patient # 0214</i>	105
13.10.2	<i>Patient # 0232</i>	106
13.10.3	<i>Patient # 0931</i>	106
13.10.4	<i>Patient # 1131</i>	106
13.10.5	<i>Patient # 14043</i>	106
13.10.6	<i>Patient # 2030</i>	107
13.11	ADVERSE EVENT DISCONTINUATIONS.....	107
13.11.1	<i>Patient 1305</i>	107
13.12	REVIEWER'S COMMENTS.....	108
14.	RISK MANAGEMENT PROGRAM.....	108
14.1	STRUCTURE.....	108
14.1.1	<i>Closed-Loop Distribution System</i>	108
14.1.2	<i>Drug Product Kit</i>	110
14.1.3	<i>Xyrem® Physician Success Program</i>	111
14.1.4	<i>Xyrem® Patient Success Program</i>	113
14.2	OPDRA COMMENTS.....	114
14.3	COMMENTS OF CONTROLLED SUBSTANCES STAFF.....	115
14.4	ADDITIONAL RISK MANAGEMENT RECOMMENDATIONS.....	115
15.	LABELING REVIEW.....	115
16.	OVERALL COMMENTS.....	115
16.1	CLINICAL SAFETY.....	115
16.2	CLINICAL EFFICACY.....	116
16.3	WITHDRAWAL PHENOMENA AND ABUSE POTENTIAL.....	116
16.4	RISK MANAGEMENT PROGRAM.....	117
16.5	ADDITIONAL COMMENTS.....	117
17.	STUDY SITE INSPECTIONS.....	117
18.	FINANCIAL DISCLOSURE CERTIFICATION.....	118
18.1	COMPONENTS OF CERTIFICATION.....	118
18.1.1	<i>Certification Pertinent To Dr Lawrence Scrima</i>	118
18.1.2	<i>Certification Pertinent To Other Investigators</i>	118
18.2	REVIEWER'S COMMENT.....	119

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.